Ligand Pharmaceuticals Incorporated (LGND) Q1 2013 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Up 2.72%

Ligand Pharmaceuticals reported a strong EPS performance, exceeding expectations significantly, which contributed to a positive stock reaction of 2.72%. The lack of revenue data and guidance may leave investors cautious, but the strong EPS suggests effective cost management and potential for future growth.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.16	N/A	+105.13%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting a focus on partnerships and future growth. However, they did not provide specific guidance for the upcoming quarters.

We are pleased with our EPS performance this quarter.

Our focus remains on strategic partnerships and product development.

Ligand Pharmaceuticals Beats on EPS, Stock Up 2.72%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Up 2.72%

Key numbers

Management commentary